Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2019, with a specific reporting date of September 11, 2019. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of insider trading activity.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2019-09-10 | Ordinary Shares (25p each) | £16.5779 | 140 shares (aggregate) | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine share acquisitions by executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as part of the standard Share Reward Plan.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs (10 executives and 1 PCA) on September 10, 2019.
- Confirm the transaction price of £16.5779 aligns with the market price on the London Stock Exchange for that date.
- Note that the volume per individual was minimal (ranging from 14 to 16 shares), indicating these are likely matching or partnership shares rather than significant open-market purchases.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial statements.